|
Early nivolumab addition to regorafenib in patients with hepatocellular carcinoma progressing under first-line therapy (GOING trial), interim analysis and safety profile. |
|
Marco Sanduzzi Zamparelli |
|
Travel, Accommodations, Expenses - Bayer; Eisai |
|
|
Consulting or Advisory Role - Bayer; Eisai; MSD; Roche; Sirtex Medical |
Speakers' Bureau - Bayer; Boston Biologics; Eisai; MSD |
|
|
Consulting or Advisory Role - Bayer; Eisai; Roche |
Speakers' Bureau - Bayer; Eisai |
|
|
Travel, Accommodations, Expenses - Bayer; Eisai |
|
|
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; MSD |
Speakers' Bureau - Abbvie; Bayer; Eisai; MSD |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Eisai |
Speakers' Bureau - Bayer; Eisai; Merck; Roche |
Research Funding - Laboratorios Viñas |
Travel, Accommodations, Expenses - Bayer; Eisai |
|
|
|
Research Funding - Generalitat de Catalunya PERIS |
|
|
Consulting or Advisory Role - Eisai; Gilead Sciences; MSD |
|
|
|
|
|
Travel, Accommodations, Expenses - Bayer |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Eisai; M Consulting |
Travel, Accommodations, Expenses - Bayer |
|
|
Consulting or Advisory Role - Roche |
Travel, Accommodations, Expenses - Bayer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Arqule; Basilea; Bayer Schering Pharma; Bristol-Myers Squibb; BTG; Eisai; Novartis; Roche; Sirtex Medical |
Speakers' Bureau - Bayer Schering Pharma |
Research Funding - Bayer Schering Pharma (Inst); Ipsen (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Ipsen |
|
|
No Relationships to Disclose |